Q&A with Dr Doug Given of Health2047 Capital Partners
Health2047 Capital Partners is not just another healthcare VC fund. It was born from the AMA’s strategic vision – devised several years ago – to help address some of the U.S. healthcare sectors largest problems at the system level. These challenges – typified by market distortion and dysfunction, regulatory complexity at both the state and national levels and decrepit legacy systems, etc – have been painfully highlighted by the recent pandemic.
As part of the plan, the AMA established the first entity of the Health2047 Group, an innovation arm – Health2047 Inc (2047 is the 200th anniversary of the founding of the AMA) – and based it on Sand Hill Rd. It has 20 senior individuals, an annual budget of $15 million ($3 million annually to seed investable concepts) and a passive $15 million capital pool provided by United Health Group, one of the world’s largest health sector companies. In recent years, the AMA and UHG have committed $135 million in aggregate to this venture, as well as significant human resources.
Join us for a private Family Office Insights Webinar featuring Dr Doug Given a serial entrepreneur and VC fund manager on a mission to transform American healthcare at the system level; Attacking the dysfunction in healthcare by seeking to remove the obstacles and burdens that interfere with patient care.
November 3, 2021 at 2:15pm-3:15pm EST
RSVP & Confirmation Required
Investors Only Please!
Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com
Dr Doug Given of Health2047 Capital Partners
Doug Given is Managing Member of Health2047 Capital Partners LLC. He served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, Doug spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. A physician and medical scientist by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a venture capitalist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO.
Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc., Board Chair at Akiri Inc. and Arrowhead Pharmaceuticals Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research (SIEPR), and The Houston Methodist Research Institute.
Doug received MD and PhD degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania and was a Clinical and Research Fellow in internal medicine and infectious diseases at Massachusetts General Hospital and Harvard Medical School.